Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
HCC1937 Topotecan
1.0
Topo I
Chemotherapy
 -0.3676 0.61187
HCC70 Cisplatin
10.0
Chemo
Chemotherapy
 -0.6832 0.61156
HCC1937 Topotecan
3.1623
Topo I
Chemotherapy
 -0.4282 0.61133
MDA-MB-468 Volasertib
0.31623
PLK
Cell cycle
 -0.4485 0.61117
HCC1937 Ceritinib
10.0
ALK
RTK
 -0.5730 0.61105
CAL-51 Buparlisib
10.0
pan PI3K
PI3K/mTOR
 -0.3883 0.61074
HCC1954 Dinaciclib
0.031623
pan CDK
Cell cycle
 -0.3351 0.60940
CAL-51 Luminespib
1.0
HSP90
Misc
 -0.3386 0.60923
HCC1954 AZD7762
10.0
CHK1/2
Cell cycle
 -0.3978 0.60880
CAL-120 ABT-737
10.0
Bcl2/XL
Misc
 -0.4339 0.60838
BT-549 AZD7762
10.0
CHK1/2
Cell cycle
 -0.4824 0.60829
BT-20 Taselisib
10.0
PI3Ka, g, d
PI3K/mTOR
 -0.3749 0.60583
SUM149PT Taselisib
10.0
PI3Ka, g, d
PI3K/mTOR
 -0.2343 0.60552
SUM149PT Taxol
0.01
Chemo
Chemotherapy
 -0.1548 0.60518
PDXHCI002 Tivantinib
1.0
MET
RTK
 -0.3731 0.60360
PDXHCI002 Vorinostat
1.0
HDAC
Misc
 -0.2956 0.60310
PDXHCI002 Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.4401 0.60190
HCC1500 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.8084 0.60186
Hs 578T Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.3466 0.60172
SK-BR-3 Dinaciclib
0.1
pan CDK
Cell cycle
 -0.5968 0.60052
PDX1258 Ceritinib
10.0
ALK
RTK
 -0.6841 0.60042
MDA-MB-157 Topotecan
10.0
Topo I
Chemotherapy
 -0.8333 0.60008
PDX1258 Doxorubicin
3.1623
Chemo
Chemotherapy
 -0.4928 0.59985
HCC70 Taxol
0.1
Chemo
Chemotherapy
 -0.4900 0.59962
SUM149PT Cisplatin
10.0
Chemo
Chemotherapy
 -0.2290 0.59945